Combination assays for evaluation of immune function and CYP3A5 genotype to identify the risk of infectious complications and mortality in living donor liver transplant patients

Annals of Transplantation

Volumn 18, Issue 1, 2013, Pages 349-357

  Mizuno, Shugo ^a   Nakatani, Kaname ^a   Muraki, Yuichi ^a   Tanemura, Akihiro ^a   Azumi, Yoshinori ^a   Kuriyama, Naohisa ^a   Ohsawa, Ichiro ^a   Kishiwada, Masashi ^a   Usui, Masanobu ^a   Sakurai, Hiroyuki ^a   Tabata, Masami ^a   Okuda, Masahiro ^a   Nobori, Tsutomu ^a   Isaji, Shuji ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcineurin inhibitor; Cytocheome P450 3A genotype; Immune functional assay; Living donor liver transplantation

Indexed keywords

CYTOCHROME P450 3A5; METHYLPREDNISOLONE; PREDNISOLONE; RAPAMYCIN; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BACTERIAL INFECTION; CHILD; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; IMMUNE FUNCTION TEST; IMMUNE STATUS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATION; SURGICAL MORTALITY;

ADOLESCENT; ADULT; AGED; BACTERIAL INFECTIONS; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GENOTYPE; HUMANS; IMMUNOASSAY; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFECTION; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; MORBIDITY; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TACROLIMUS; YOUNG ADULT;

EID: 84887250956     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.883974     Document Type: Article

References (16)

1. Kowalski R, Post D, Schneider MC et al: Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant, 2003; 17: 77-88
2. Mizuno S, Hamada T, Nakatani K et al: Monitoring peripheral blood CD4+ adenosine triphosphate activity after living donor liver transplantation: impact of combination assays of immune function and CYP3A5 genotype. J Hepatobiliary Pancreat Sci, 2011; 18(2): 226-32; discussion 232-34
3. Kowalski R, Post D, Mannon RB et al: Assessing relative risks of infection and rejection: a metaanalysis using an immune function assay. Transplantation, 2006; 82: 663-68
4. Israeli M, Yussim A, Mor E et al: Preceeding the rejection: In search for a comprehensive posttransplant immune monitoring platform. Transpl Immunol, 2007; 18: 7-12
5. Berglund D, Bengtsson M, Biglarnia A et al: Screening of mortality in transplant patients using an assay for immune function. Transpl Immunol, 2011; 24(4): 246-50
6. Shiraga T, Matsuda H, Nagase K et al: Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem. Pharmacol, 1994; 47: 727-35
7. Hesselink DA, van Schaik RH, van der Heiden IP et al: Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther, 2003: 74: 245-54
8. Kamdem LK, Streit F, Zanger UM et al: Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem, 2005: 51: 1374-81
9. Dai Y, Hebert MF, Isoherranen N et al: Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos, 2006; 34: 836-47
10. Muraki Y, Usui M, Isaji S et al: Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients. Ann Transplant, 2011; 16(4): 55-62
11. Usui M, Isaji S, Kobayashi M et al: Selection of calcineurin inhibitar after living-donor liver transplantation based on CYP3A5 gene polymorphism: attempt of tailor-made treatment introduction. Am J Transplant, 2007; 7(Suppl. 2): 1562
12. Fukuen S, Fukuda T, Maune H et al: Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population. Pharmacogenetics, 2002; 12: 331-34
13. Jun KR, Lee W, Jang MS et al: Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea. Transplantation, 2009; 87(8): 1225-31
14. Hosohata K, Masuda S, Yonezawa A et al: Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control study. Drug Metab Pharmacokinet, 2009; 24(5): 458-63
15. Aberg F, Pukkala E, Höckerstedt K et al: Risk of malignant neoplasms after liver transplantation: a population-based study. Liver Transpl, 2008; 14(10): 1428-36
16. Cheng JW, Shi YH, Fan J et al: An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol, 2011; 137(10): 1445-53